Qualigen Therapeutics Inc. (NASDAQ: QLGN) is 5.62% higher on its value in year-to-date trading and has touched a low of $3.71 and a high of $30.75 in the current 52-week trading range. The QLGN stock was last observed hovering at around $4.46 in the recent trading session, with the current gains setting it 0.02% off its average median price target of $175.00 for the next 12 months. It is also 97.44% off the consensus price target high of $175.00 offered by 1 analysts, but current levels are 97.44% higher than the price target low of $175.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $4.48, the stock is -2.24% and -41.55% below its SMA20 and SMA50 respectively. However, with a current trading volume of 0.47 million and changing 0.45% at the moment leaves the stock -32.39% off its SMA200. QLGN registered -82.51% loss for a year compared to 6-month loss of -21.72%. The firm has a 50-day simple moving average (SMA 50) of $5.0588 and a 200-day simple moving average (SMA200) of $6.9724.
The stock witnessed a -17.71% gain in the last 1 month and extending the period to 3 months gives it a -27.77%, and is 8.78% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.73% over the week and 12.12% over the month.
Qualigen Therapeutics Inc. (QLGN) has around 5 employees, a market worth around $53.30M and $5.41M in sales. Distance from 52-week low is 20.75% and -85.43% from its 52-week high.
Qualigen Therapeutics Inc. (QLGN) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Qualigen Therapeutics Inc. (QLGN) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 3.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Qualigen Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 71.10% this year.
Qualigen Therapeutics Inc. (QLGN) Top Institutional Holders
The shares outstanding are 34.91M, and float is at 9.64M with Short Float at 2.57%.
Qualigen Therapeutics Inc. (QLGN) Insider Activity
A total of 8 insider transactions have happened at Qualigen Therapeutics Inc. (QLGN) in the last six months, with sales accounting for 3 and purchases happening 5 times.